The gene products of Itgal and Itgb3 are targeted by, respectively, lifitegrast, approved to treat dry eye, and eptifibatide, which inhibits platelet aggregation and is approved to manage myocardial infarction. The gene discussed is ITGB3; the disease is Keratoconjunctivitis sicca.